Literature DB >> 1859492

Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action.

M B Kahaleh1.   

Abstract

The vascular endothelium is an important functional unit in the regulation of the vascular and perivascular environment. Various chemical and physical stimuli mediate an endothelial-dependent vasoconstriction through the release of endothelial soluble factors, such as the recently recognized endothelium-derived vasoconstrictor peptide called endothelin. The presence of circulating endothelin and the effect of cold exposure on plasma endothelin levels were investigated in patients with scleroderma and in healthy control subjects. Radioimmunoassay demonstrated a mean +/- SD plasma level of 10.7 +/- 7.3 pg/ml in the patients (n = 19) and 3.7 +/- 2 in the control subjects (n = 16) (P less than 0.005). These levels were also assessed in 5 control subjects and 5 scleroderma patients before and after 30 minutes of total body cooling (to 15 degrees C). The endothelin level did not change significantly in either group; however, 2 scleroderma patients showed a significant increase after cooling. The effects of endothelin on fibroblast proliferation and collagen synthesis were evaluated in order to assess the impact of released endothelin on the interstitium. A significant mitogenic effect and a collagen synthesis-enhancing effect, which were dose-dependent, were seen. The strong, characteristically prolonged, vasoconstrictor activity coupled with the profibrotic effect demonstrated here make it likely that disturbances in the control of endothelin production can contribute to the pathogenesis of scleroderma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1859492     DOI: 10.1002/art.1780340807

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  35 in total

1.  Plasma endothelin-1 levels in Behçet's disease.

Authors:  T Uslu; C Erem; M Tosun; O Deger
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

2.  Investigation of the association between Rho/Rho-kinase gene polymorphisms and systemic sclerosis.

Authors:  Yavuz Pehlivan; Servet Yolbas; Gozde Yıldırım Cetin; Fatma Alibaz-Oner; Yonca Cagatay; Neslihan Yilmaz; Serdar Oztuzcu; Salim Donmez; Metin Ozgen; Suleyman Serdar Koca; Omer Nuri Pamuk; Mehmet Sayarlıoglu; Bunyamin Kisacik; Haner Direskeneli; Abdullah Tuncay Demiryurek; Ahmet Mesut Onat
Journal:  Rheumatol Int       Date:  2015-11-28       Impact factor: 2.631

Review 3.  The association between systemic sclerosis, arginine and asymmetric dimethylarginine.

Authors:  Li Zhang; Ya-Nan Wan; Jiu-Hua Zhao; Yu-Jie Wang; Ying-Xin Wang; Jun-Wei Yan; Xiao-Lei Huang; Jing Wang
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

4.  Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon.

Authors:  A E Smyth; A L Bell; I N Bruce; S McGrann; J A Allen
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

Review 5.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

6.  Endothelin-1 in idiopathic pulmonary fibrosis.

Authors:  M Uguccioni; L Pulsatelli; B Grigolo; A Facchini; L Fasano; C Cinti; M Fabbri; G Gasbarrini; R Meliconi
Journal:  J Clin Pathol       Date:  1995-04       Impact factor: 3.411

Review 7.  The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Jeffrey J Swigris; Kevin K Brown
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

8.  Correlation between congenital heart disease complicated with pulmonary artery hypertension and circulating endothelial cells as well as endothelin-1.

Authors:  Xiaofei Li; Jun Qiu; Min Pan; Dongdong Zheng; Yamin Su; Meifang Wei; Xiangqing Kong; Wei Sun; Jiahua Zhu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 9.  Coronary microvascular disease in chronic Chagas cardiomyopathy including an overview on history, pathology, and other proposed pathogenic mechanisms.

Authors:  Marcos A Rossi; Herbert B Tanowitz; Lygia M Malvestio; Mara R Celes; Erica C Campos; Valdecir Blefari; Cibele M Prado
Journal:  PLoS Negl Trop Dis       Date:  2010-08-31

10.  Does targeting the lipophilic milieu provide advantages for an endothelin antagonist?

Authors:  David M Pollock; Erika I Boesen; Stephen M Black
Journal:  Mol Interv       Date:  2009-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.